Mitchell Sinkler & Starr PA Buys Shares of 2,800 Edwards Lifesciences Co. (NYSE:EW)

Mitchell Sinkler & Starr PA purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,800 shares of the medical research company’s stock, valued at approximately $240,000.

Other large investors also recently made changes to their positions in the company. DSM Capital Partners LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $28,000. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $29,000. Riverview Trust Co purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth $34,000. Finally, Pingora Partners LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $38,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 1.7 %

Shares of Edwards Lifesciences stock opened at $68.25 on Thursday. The business has a 50-day moving average of $73.32 and a 200-day moving average of $83.72. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The company has a market capitalization of $41.11 billion, a PE ratio of 29.42, a P/E/G ratio of 2.79 and a beta of 1.13. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the firm earned $0.66 earnings per share. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,133,916.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,133,916.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,250 shares of company stock worth $1,218,138. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on EW. Stifel Nicolaus cut their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Citigroup increased their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. UBS Group cut their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday. Barclays cut their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Fifteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $80.81.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.